In early 2022, I recall seeing another shift in utilization from GLP-1s with less weight loss benefit (Victoza, Soliqua, Trulicity, etc.) to Ozempic and Mounjaro, creating a consolidation in usage that along with other factors likely led to minor rebate improvement but increased initial costs
-- (Propionyl-L-carnitine):
The unique generation and function of active GLP-1 has influenced growing interest in the hormone, and its reputation as an important biomarker in type 2 diabetes research 16,21,23
Continuous variables, such as VAS, OHIP-14 K, and supplementary assessments (ease of use of the treatment and satisfaction with symptom relief), were analyzed using one-way ANOVA or the KruskalWallis test, as appropriate
The treatment is painless and typically takes less than an hour to complete
But GLP-1 receptor agonists have done just that